Four consecutive earnings beats averaging approximately 11% above consensus and free cash flow converting at roughly 3x reported net income demonstrate operational and cash generation strength; however, the stock has moved above its near-term resistance target with an unfavorable risk/reward setup and overbought momentum readings at an RSI of 83, arguing for patience rather than action at current prices.
Thesis pillars
- Sole Supplier Concentration Risk↑Improving
- Consistent Earnings Beat Streak↑Improving
- Exceptional Free Cash Generation→Stable
- +1 more pillar — see the Why tab for full reasoning
Cardinal Health, Inc. (CAH) Stock Analysis
Breakout setup
Healthcare · Medical Distribution
Sell if holding. Engine safety override at $239.35: Quality below floor (3.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10. Specifically: Below-average business quality.
Cardinal Health is a global healthcare services and products company serving hospitals, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients at home, organized around its Pharmaceutical and Specialty Solutions and Global Medical Products... Read more
Sell if holding. Engine safety override at $239.35: Quality below floor (3.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10. Specifically: Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 58, MACD bullish. Score 5.9/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 63d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
About Cardinal Health, Inc.
About Cardinal Health, Inc.
Cardinal Health's largest customer, CVS Health, accounted for 30% of fiscal 2025 revenue, with its five largest customers together representing 43% and two group purchasing organizations, Vizient and Premier, contributing another 27% through member networks. The company operates two primary segments — Pharmaceutical and Specialty Solutions and Global Medical Products and Distribution (GMPD) — plus Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight Logistics, employing approximately 57,700 people globally.
Cardinal Health's Pharmaceutical and Specialty Solutions segment earns margin from its generic pharmaceutical program (price discounts, rebates, and service fees from manufacturers, highest shortly after a generic's launch and declining over time), from distribution services agreements with branded manufacturers compensated as a percentage of wholesale acquisition cost, and from specialty pharmaceutical distribution and consulting services. A generic-sourcing joint venture with CVS Health, Red Oak Sourcing, negotiates supply contracts on both companies' behalf through June 2029. The GMPD segment manufactures higher-margin Cardinal Health-branded medical, surgical, and laboratory products alongside lower-margin distribution of third-party national-brand products. The company has been actively acquiring specialty-care assets, including ADS ($1.1 billion, diabetes supplies), a 73% stake in GI Alliance ($2.8 billion, gastroenterology MSO), Urology America ($360 million), Integrated Oncology Network ($1.1 billion), and Specialty Networks ($1.2 billion), expanding its physician-practice management platforms.
Show full overview
Cardinal Health remains bound by injunctive-relief terms from its 2022 opioid settlement (the NOSA), which requires an independent monitor to oversee its controlled-substance anti-diversion program through 2027 and funding of a third-party data-aggregation clearinghouse through 2032 — concrete, dated obligations layered on top of ordinary DEA and state pharmacy-board oversight. Separately, the company disclosed a November 2023 Civil Investigative Demand from the Department of Justice examining potential Anti-Kickback Statute and False Claims Act issues tied to a 2022 GPO and rheumatology MSO acquisition, and it is cooperating with that inquiry. A compliance failure in any one specialty-care acquisition could jeopardize Medicare or 340B program participation across the company's fast-growing physician-services business.
See also: Healthcare · Medical Distribution
From Cardinal Health, Inc.'s most recent 10-K filing, extracted August 23, 2026.
Recent developments
updated 2026-09-02Recent Developments — Cardinal Health, Inc.
Latest news
- NEWS RBC Capital Initiates Coverage On Cardinal Health with Outperform Rating, Announces Price Target of $276 — benzinga Aug 19, 2026 positive
- NEWS TD Cowen Maintains Buy on Cardinal Health, Raises Price Target to $280 — benzinga Aug 13, 2026 positive
- NEWS JP Morgan Maintains Neutral on Cardinal Health, Raises Price Target to $260 — benzinga Aug 13, 2026 positive
- NEWS Barclays Maintains Overweight on Cardinal Health, Raises Price Target to $275 — benzinga Aug 13, 2026 positive
- NEWS Evercore ISI Group Maintains Outperform on Cardinal Health, Raises Price Target to $270 — benzinga Aug 12, 2026 positive
Generated 2026-09-03T16:17:15Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $239.35: Quality below floor (3.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10. Specifically: Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 58, MACD bullish. Prior stop was $229.45. Score 5.9/10, moderate confidence.
Take-profit target: $243.84 (+1.9% upside). Prior stop was $229.45. Stop-loss: $229.45.
Target reached (1.9% upside); Quality below floor (3.6 < 4.0).
Cardinal Health, Inc. trades at a P/E of 32.5 (forward 17.0). TrendMatrix value score: 6.0/10. Verdict: Sell.
24 analysts cover CAH with a consensus score of 4.2/5. Average price target: $271.
What does Cardinal Health, Inc. do?Cardinal Health is a global healthcare services and products company serving hospitals, pharmacies, ambulatory surgery...
Cardinal Health is a global healthcare services and products company serving hospitals, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients at home, organized around its Pharmaceutical and Specialty Solutions and Global Medical Products and Distribution (GMPD) segments, plus Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight Logistics. The company's largest customer, CVS Health, accounted for 30% of fiscal 2025 revenue, its five largest customers for 43%, and its five largest suppliers for 37%, across approximately 57,700 emplo